Eric J. Duncavage
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Eric J. Duncavage has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
Haley J. Abel
Washington University School of Medicine, Saint Louis, Missouri
5 shared publicationsCatherine E. Cottrell
Department of Pathology and Immunology, Washington University in St. Louis, Missouri 63130, USA
3 shared publicationsJohn D. Pfeifer
Department of Pathology and Immunology, Washington University, St. Louis, Missouri
3 shared publications- Patrick J. Cimino
Center for Cancer and Immunology Research, Division of Pathology and Laboratory Medicine, Children’s National Research Institute, Washington, DC, USA
3 shared publications Carla Wilson
2 shared publications- Christina M. Lockwood
Department of Laboratory Medicine and Pathology, University of Washington School of Medicine , Seattle, WA
2 shared publications
Latest Publications
- Open Access
- 23 August 2017
- Published by Cold Spring Harbor Laboratory in Cold Spring Harbor Molecular Case Studies
- Vol. 3 (6) , a001495
FGFR2 amplification in colorectal adenocarcinoma
FGFR2 is recurrently amplified in 5% of gastric cancers and 1%–4% of breast cancers; however, this molecular alteration has never been reported in a primary colorectal cancer specimen. Preclinical studies indicate that several FGFR tyrosine-kinase inhibitors (TKIs), such as AZD4547, have in vitro activity against the FGFR2-amplified colorectal cell line, NCI-H716. The efficacy of these inhibitors is currently under investigation in clinical trials for breast and gastric cancer. Thus, better characterizing colorectal tumors for FGFR2 amplification could identify a subset of patients who may benefit from FGFR TKI therapies. Here, we describe a novel FGFR2 amplification identified by clinical next-generation sequencing in a primary colorectal cancer. Further characterization of the tumor by immunohistochemistry showed neuroendocrine differentiation, similar to the reported properties of the NCI-H716 cell line. These findings demonstrate that the spectrum of potentially clinically actionable mutations detected by targeted clinical sequencing panels is not limited to only single-nucleotide polymorphisms and insertions/deletions but also to copy-number alterations.
- 23 August 2017
- Published by Cold Spring Harbor Laboratory in Cold Spring Harbor Molecular Case Studies
- Vol. 3 (6) , a001495
Open AccessFGFR2 amplification in colorectal adenocarcinoma
FGFR2 is recurrently amplified in 5% of gastric cancers and 1%–4% of breast cancers; however, this molecular alteration has never been reported in a primary colorectal cancer specimen. Preclinical studies indicate that several FGFR tyrosine-kinase inhibitors (TKIs), such as AZD4547, have in vitro activity against the FGFR2-amplified colorectal cell line, NCI-H716. The efficacy of these inhibitors is currently under investigation in clinical trials for breast and gastric cancer. Thus, better characterizing colorectal tumors for FGFR2 amplification could identify a subset of patients who may benefit from FGFR TKI therapies. Here, we describe a novel FGFR2 amplification identified by clinical next-generation sequencing in a primary colorectal cancer. Further characterization of the tumor by immunohistochemistry showed neuroendocrine differentiation, similar to the reported properties of the NCI-H716 cell line. These findings demonstrate that the spectrum of potentially clinically actionable mutations detected by targeted clinical sequencing panels is not limited to only single-nucleotide polymorphisms and insertions/deletions but also to copy-number alterations.
- 1 March 2017
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 19 (2) , 328-337
Targeted Next-Generation Sequencing in Molecular Subtyping of Lower-Grade Diffuse Gliomas
- 1 March 2017
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 19 (2) , 328-337
Targeted Next-Generation Sequencing in Molecular Subtyping of Lower-Grade Diffuse Gliomas
- 1 February 2017
- Published by Elsevier in Experimental and Molecular Pathology
- Vol. 102 (1) , 156-161
Spectrum of mutations in leiomyosarcomas identified by clinical targeted next-generation sequencing
- 1 February 2017
- Published by Elsevier in Experimental and Molecular Pathology
- Vol. 102 (1) , 156-161
Spectrum of mutations in leiomyosarcomas identified by clinical targeted next-generation sequencing
- Open Access
- 30 August 2016
- Published by Springer Nature in Leukemia
- Vol. 30 (12) , 2422-2426
Targeted sequencing informs the evaluation of normal karyotype cytopenic patients for low-grade myelodysplastic syndrome
- 30 August 2016
- Published by Springer Nature in Leukemia
- Vol. 30 (12) , 2422-2426
Open AccessTargeted sequencing informs the evaluation of normal karyotype cytopenic patients for low-grade myelodysplastic syndrome
- 15 April 2016
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 140 (11) , 1225-1227
Template for Reporting Results of Biomarker Testing of Specimens From Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Article Citation: Eric Duncavage, Ranjana H. Advani, Steven Agosti, Philip Foulis, Christine Gibson, Loveleen Kang, Joseph D. Khoury, L. Jeffrey Medeiros, Robert S. Ohgami, Dennis P. O'Malley, Keyur P. Patel, Jason N. Rosenbaum, Carla Wilson, and for the Members of the Cancer Biomarker Reporting Committee, College of American Pathologists (2016) Template for Reporting Results of Biomarker Testing of Specimens From Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified. Archives of Pathology & Laboratory Medicine: November 2016, Vol. 140, No. 11, pp. 1225-1227. https://doi.org/10.5858/arpa.2015-0418-CP
- 15 April 2016
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 140 (11) , 1225-1227
Template for Reporting Results of Biomarker Testing of Specimens From Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Article Citation: Eric Duncavage, Ranjana H. Advani, Steven Agosti, Philip Foulis, Christine Gibson, Loveleen Kang, Joseph D. Khoury, L. Jeffrey Medeiros, Robert S. Ohgami, Dennis P. O'Malley, Keyur P. Patel, Jason N. Rosenbaum, Carla Wilson, and for the Members of the Cancer Biomarker Reporting Committee, College of American Pathologists (2016) Template for Reporting Results of Biomarker Testing of Specimens From Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified. Archives of Pathology & Laboratory Medicine: November 2016, Vol. 140, No. 11, pp. 1225-1227. https://doi.org/10.5858/arpa.2015-0418-CP
- 15 April 2016
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 140 (11) , 1228-1230
Template for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Article Citation: Eric Duncavage, Ranjana H. Advani, Steven Agosti, Philip Foulis, Christine Gibson, Loveleen Kang, Joseph D. Khoury, L. Jeffrey Medeiros, Robert S. Ohgami, Dennis P. O'Malley, Keyur P. Patel, Jason N. Rosenbaum, Carla Wilson, and for the Members of the Cancer Biomarker Reporting Committee, College of American Pathologists (2016) Template for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Archives of Pathology & Laboratory Medicine: November 2016, Vol. 140, No. 11, pp. 1228-1230. https://doi.org/10.5858/arpa.2016-0045-CP
- 15 April 2016
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 140 (11) , 1228-1230
Template for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Article Citation: Eric Duncavage, Ranjana H. Advani, Steven Agosti, Philip Foulis, Christine Gibson, Loveleen Kang, Joseph D. Khoury, L. Jeffrey Medeiros, Robert S. Ohgami, Dennis P. O'Malley, Keyur P. Patel, Jason N. Rosenbaum, Carla Wilson, and for the Members of the Cancer Biomarker Reporting Committee, College of American Pathologists (2016) Template for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Archives of Pathology & Laboratory Medicine: November 2016, Vol. 140, No. 11, pp. 1228-1230. https://doi.org/10.5858/arpa.2016-0045-CP
- Open Access
- 1 August 2015
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 73 (2) , 228-236.e2
T-cell clonality assessment by next-generation sequencing improves detection sensitivity in mycosis fungoides
- 1 August 2015
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 73 (2) , 228-236.e2
Open AccessT-cell clonality assessment by next-generation sequencing improves detection sensitivity in mycosis fungoides
- 14 May 2015
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 37 (S1) , 115-121
The utility of next‐generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes
Summary: Myeloid malignancies including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are a heterogeneous group of disorders that share a common biology and are a major source of morbidity and mortality. In the last several years, studies using next‐generation sequencing (NGS) have identified a core set of recurrently mutated myeloid malignancy genes in the majority of patients with AML and MDS, including those with normal cytogenetics. DNA‐level mutations in several of these genes including NPM1, FLT3, and CEBPA in AML and ASXL1, ETV6, EZH2, RUNX1, and TP53 in MDS are associated with changes in patient outcomes and are now tested for in clinical laboratories. In addition to providing prognostic information, these gene mutations can be used to monitor patient disease burden through the use of ultrasensitive detection techniques. In this review, we will focus on the clinical utility of various NGS‐based methods including whole‐genome sequencing, exome sequencing, and targeted panel‐based sequencing in the initial diagnosis and management of AML and MDS and cover recent methodological advances for the molecular monitoring of AML and MDS.
- 14 May 2015
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 37 (S1) , 115-121
The utility of next‐generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes
Summary: Myeloid malignancies including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are a heterogeneous group of disorders that share a common biology and are a major source of morbidity and mortality. In the last several years, studies using next‐generation sequencing (NGS) have identified a core set of recurrently mutated myeloid malignancy genes in the majority of patients with AML and MDS, including those with normal cytogenetics. DNA‐level mutations in several of these genes including NPM1, FLT3, and CEBPA in AML and ASXL1, ETV6, EZH2, RUNX1, and TP53 in MDS are associated with changes in patient outcomes and are now tested for in clinical laboratories. In addition to providing prognostic information, these gene mutations can be used to monitor patient disease burden through the use of ultrasensitive detection techniques. In this review, we will focus on the clinical utility of various NGS‐based methods including whole‐genome sequencing, exome sequencing, and targeted panel‐based sequencing in the initial diagnosis and management of AML and MDS and cover recent methodological advances for the molecular monitoring of AML and MDS.
- 22 April 2015
- Published by Elsevier in Experimental and Molecular Pathology
- Vol. 98 (3) , 568-573
A wide spectrum of EGFR mutations in glioblastoma is detected by a single clinical oncology targeted next-generation sequencing panel
- 22 April 2015
- Published by Elsevier in Experimental and Molecular Pathology
- Vol. 98 (3) , 568-573
A wide spectrum of EGFR mutations in glioblastoma is detected by a single clinical oncology targeted next-generation sequencing panel
- Open Access
- 1 July 2014
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 16 (4) , 405-417
Detection of Gene Rearrangements in Targeted Clinical Next-Generation Sequencing
- 1 July 2014
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 16 (4) , 405-417
Open AccessDetection of Gene Rearrangements in Targeted Clinical Next-Generation Sequencing